A cute cardiogenic pulmonary edema is a common medical emergency that accounts for up to 1 million hospital admissions for acute conditions per year in the United States. 1 It is a leading cause of hospitalization, accounting for 6.5 million hospital days each year. 2 In-hospital mortality from acute cardiogenic pulmonary edema is high (10 to 20%), 3 especially when it is associated with acute myocardial infarction. 4 Patients who do not have a response to initial therapy often require tracheal intubation and ventilation, with the associated potential for complications. 5 Noninvasive methods of ventilation can avert tracheal intubation by improving oxygenation, reducing the work of breathing, and increasing cardiac output. 6-9 Two common noninvasive methods involve continuous positive airway pressure (CPAP) or noninvasive intermittent positivepressure ventilation (NIPPV) delivered with the use of a face mask. CPAP maintains the same positivepressure support throughout the respiratory cycle, whereas NIPPV increases airway pressure more during inspiration than during expiration. As compared with CPAP, NIPPV produces greater improvements in oxygenation and carbon dioxide clearance and a greater reduction in the work of breathing in patients with pulmonary edema. 10 Clinical studies of noninvasive ventilation in patients with acute cardiogenic pulmonary edema include case series and small, randomized, controlled trials. Most compare CPAP or NIPPV with standard therapy and suggest that noninvasive ventilation improves symptoms, physiological variables, and rates of invasive ventilation. [11] [12] [13] [14] Recently published systematic reviews have suggested reduced mortality in patients treated with CPAP. [15] [16] [17] [18] Comparison of CPAP with NIPPV reveals no significant difference between the two interventions, despite the postulated physiological advantages of NIPPV. One meta-analysis suggested an increase in the rate of acute myocardial infarction in patients treated with NIPPV. 16 To date, all randomized, controlled trials known to us have been small, and most have been conducted at single centers. [15] [16] [17] [18] There has been considerable variation in study populations, the type of ventilation intervention, concomitant therapies, and trial end points. 16 Therefore, it is uncertain whether these results are either generalizable or robust. In light of this uncertainty, we conducted a large, randomized, controlled trial involving patients with acute cardiogenic pulmonary edema to determine whether noninvasive ventilation improves survival and whether NIPPV is superior to CPAP.
Me thods

Patients
Patients were recruited from 26 emergency departments in district and regional hospitals in the United Kingdom between July 2003 and April 2007. The study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice guidelines of the United Kingdom Medical Research Council, complied with the United Kingdom Data Protection Act 1998, and was approved by the Scotland A Research Ethics Committee (02/0/074, U.K.).
The inclusion criteria were an age of more than 16 years, a clinical diagnosis of acute cardiogenic pulmonary edema, pulmonary edema shown by a chest radiograph, a respiratory rate of more than 20 breaths per minute, and an arterial hydrogenion concentration of greater than 45 nmol per liter (pH <7.35). The exclusion criteria were a requirement for a lifesaving or emergency intervention, such as primary percutaneous coronary intervention; inability to give consent; or previous recruitment into the trial. All patients received standard concomitant therapy for acute pulmonary edema.
Depending on the severity of the illness, informed written or witnessed oral consent from the patient or witnessed consent from a relative was obtained at entry into the study. Whenever possible, written consent for continued participation in the trial was obtained from the patient in the subsequent 7 days.
Study Design
The study was an open, randomized, controlled, parallel-group trial with three treatment groups: standard oxygen therapy, CPAP, and NIPPV. Patients were randomly assigned to one of the three treatments at a 1:1:1 ratio with the use of a 24-hour telephone randomization service. The randomization sequence was stratified according to center, with variable block length. inspired oxygen of 0.6 in order to maintain peripheral oxygen saturation above 92%. CPAP was commenced at 5 cm of water and increased to a maximum of 15 cm of water. NIPPV was started at an inspiratory positive airway pressure of 8 cm of water and an expiratory positive airway pressure of 4 cm of water and was increased to a maximum inspiratory pressure of 20 cm of water and a maximum expiratory pressure of 10 cm of water. Patients assigned to standard medical therapy received supplemental oxygen to maintain saturations above 92% through a variable-delivery oxygen mask with a reservoir. All patients received their assigned treatment for a minimum of 2 hours. Further use of CPAP, NIPPV, or intubation (invasive ventilation) was at the discretion of the treating clinician. The trial protocol allowed early intubation if the patient did not have a sustained response with CPAP or NIPPV.
The trial was coordinated from Edinburgh and supported by a regional network of research nurses and clinicians. To ensure core competency in the use of noninvasive ventilators, training was delivered at multiple levels, including regional research nurses, site leaders, and the manufacturer of the ventilator.
Response to Therapy
Repeat analyses of arterial blood gases were performed 1 hour after recruitment. Pulse rate, respiratory rate, oxygen saturation, and noninvasively measured blood pressure were recorded at 1 hour and 2 hours. The patients reported their degree of dyspnea on a visual-analogue scale ranging from 0 (no breathlessness) to 10 (maximal breathlessness) at recruitment and at 1 hour.
Outcome Measures
The primary end point for the comparison between noninvasive ventilation (NIPPV or CPAP) and standard oxygen therapy was death within 7 days after the initiation of treatment. The primary end point for the comparison between NIPPV and CPAP was a composite of death within 7 days or tracheal intubation within 7 days. The a priori secondary end points were dyspnea, physiological variables, intubation within 7 days, length of hospital stay, admission to the critical care unit, and death within 30 days.
Myocardial infarction was defined according to the 1971 criteria of the World Health Organization and the criteria of the universal definition of myocardial infarction. 19 Two cardiologists who were unaware of the treatment assignments classified the patients as having definite myocardial infarction, probable myocardial infarction, possible myocardial infarction, or no myocardial infarction. Newly diagnosed cases of myocardial infarction were defined as cases of definite or probable myocardial infarction.
Statistical Analysis
The data and safety monitoring committee ensured that the criteria for early termination due to either efficacy (according to the Peto-Haybittle guidelines, with a criterion of P<0.001) or harm (P<0.05) of the treatment were not met.
To have an 80% chance of detecting an absolute difference of 6% in mortality (9% vs. 15%) with the use of a two-sided test with a significance level of 0.05, we needed 400 patients assigned to standard facial oxygen therapy and 800 patients assigned to either CPAP or NIPPV. With 400 patients each in the CPAP and NIPPV groups, the trial had 80% power, with the use of a two-sided test with a significance level of 0.05, to detect an absolute difference of approximately 7% in the composite end point (18% vs. 11%) and of approximately 6% in mortality (12% vs. 6%).
The data were analyzed according to the intention-to-treat principle. The primary analysis compared the rates of 7-day mortality in each group with the use of a logistic-regression model with the degrees of freedom for differences among the three treatments decomposed into the two orthogonal contrasts of standard therapy versus noninvasive therapy (CPAP or NIPPV) and CPAP versus NIPPV. Kaplan-Meier survival curves were plotted for the same comparisons, and survival was compared among the groups with the use of the log-rank test. The rates of 30-day mortality, myocardial infarction, intubation within 7 days, admission to the critical care unit (intensive or coronary care), and the composite end point of death or intubation were compared with the use of logistic regression. At 1 hour after initiation of treatment, changes in dyspnea score, physiological variables, and arterial blood gas values were compared with the use of Student's t-test. A twosided P value of less than 0.05 was considered to indicate statistical significance.
Logistic regression was used to explore interactions between treatment effect (noninvasive ventilatory support vs. standard therapy) and severity of illness, which was defined a priori according to baseline arterial pH and post hoc according to systolic blood pressure. 20, 21 Further exploratory analyses examined the interaction between treatment effect and age, sex, presence or absence of previous heart failure, and presence or absence of acute myocardial infarction.
R esult s
Of 1842 potentially eligible patients, 1511 were screened and 1156 underwent randomization. Eighty-seven patients were excluded after randomization because of ineligibility or previous recruitment into the trial (see the Supplementary Appendix, available with the full text of this article at www.nejm.org). There were no significant differences in baseline characteristics among the three groups (Table 1 ). The patients were elderly (mean [±SD] age, 77.7±9.7 years) and had marked tachycardia, tachypnea, hypertension, acidosis, and hypercapnia. Most of the patients (56.9%) were women.
Trial Intervention
Patients and concomitant therapies were evenly assigned across the intervention groups (Table 2 ; also see the Supplementary Appendix). Although the overall completion rates were similar, standard oxygen therapy was associated with a greater failure rate due to respiratory distress, whereas noninvasive ventilation, especially NIPPV, was associated with a higher rate of noncompletion due to patient discomfort ( Table 2 ). The mean duration of therapy was 2.2±1.5 hours for CPAP and 2.0±1.3 hours for NIPPV.
Primary Outcomes
There was no significant difference in the primary end point of 7-day mortality between patients receiving noninvasive ventilation (CPAP or NIPPV) (9.5%) and those receiving standard oxygen therapy (9.8%; odds ratio, 0.97; 95% confidence interval [CI] , 0.63 to 1.48; P = 0.87) ( Fig. 1 and Table 3 ). The 7-day mortality rate in nonrecruited patients was 9.9%. The rate of the primary composite end point of death or intubation within 7 days ( Fig. 1 and Table 4 ) was similar for the CPAP and the NIPPV groups (11.7% and 11.1%, respectively; odds ratio, 0.94; 95% CI, 0.59 to 1.51; P = 0.81). There were no interactions between treatment effect and severity of illness, as defined by either baseline arterial pH (P = 0.94) or systolic blood pressure (P = 0.17). Further exploratory subgroup analysis found no interactions between treatment effect and age (P = 0.52), sex (P = 0.33), presence or absence of a history of heart failure (P = 0.28), and presence or absence of myocardial infarction at presentation (P = 0.93).
Secondary Outcomes
There was no significant difference in the 30-day mortality rate between patients receiving standard oxygen therapy and those receiving noninvasive ventilation (16.4% and 15.2%, respectively; odds ratio, 0.92; 95% CI, 0.64 to 1.31; P = 0.64) ( Table 3) . Mortality rates were similar in the CPAP and the NIPPV groups at 7 days (9.6% and 9.4%, respectively; odds ratio, 0.97; P = 0.91) and at 30 days (15.4% and 15.1%, respectively; odds ratio, 0.98; P = 0.92) ( Table 4) . Noninvasive ventilation (CPAP or NIPPV) was associated with greater reductions in dyspnea, heart rate, acidosis, and hypercapnia than was standard oxygen therapy (Table 3) . Patients receiving standard oxygen therapy and those receiving noninvasive ventilation had similar rates of tracheal intubation, admission to the critical care unit, and myocardial infarction. Patients receiving CPAP and those receiving NIPPV also had similar rates of these outcomes (Table 4) .
Discussion
Despite early improvements in symptoms and in surrogate measures of disease severity, we found no difference in the effect on short-term mortality between standard oxygen therapy and noninvasive ventilation. Furthermore, there were no major differences in treatment efficacy or safety between the two noninvasive ventilation treatments, CPAP and NIPPV.
Meta-analyses and systematic reviews of immediate treatment with noninvasive ventilation in patients with acute cardiogenic pulmonary edema have reported a 47% reduction in mortality. 15 The Three Interventions in Cardiogenic Pulmonary Oedema (3CPO) trial was adequately powered to assess an effect of this magnitude and recruited more patients than the total number of patients included in these analyses and reviews. Although the 95% confidence intervals overlap with results from meta-analyses, the 3CPO trial showed no effect of treatment with noninvasive ventilation on mortality.
Was the study population inappropriate? On the basis of the results of previous studies, we applied strict inclusion and exclusion criteria and completed this large trial. The baseline characteristics and event rates were similar to those in previous studies and indicate that we recruited patients with severe disease. There was no evidence of patient-selection bias, since the 7-day mortality rates among nonrecruited patients (9.9%) were virtually the same as those among patients who were recruited to the trial (9.6%). In keeping with previous analyses, 16 there was no interaction between treatment effect and the severity of disease, a result suggesting that the inclusion of those with milder disease did not obscure potential benefits in the sickest patients. We therefore believe that we targeted and assessed the correct patient population. Was the intervention correctly delivered? More than 80% of the centers had experience with the use of noninvasive ventilation before the start of the trial. There was a comprehensive training program for all centers to ensure the competence and consistency of the operators of the ventilation devices throughout the trial. We used a readily applied portable ventilator that allows both CPAP and NIPPV to be used and is not affected by leaks around the face mask of up to 50 liters per minute. Although we did not measure the concentration of inspired oxygen, the circuit delivers oxygen in concentrations of up to 60%. There was an apparent drop in the partial pressure of arterial oxygen after treatment with noninvasive ventilation at 1 hour, but the size of the decrease was moderate and of questionable clinical relevance. Indeed, in contrast to standard oxygen therapy, there were no treatment failures due to worsening hypoxia in the noninvasive-ventilation groups. The mean pressures in both the CPAP group (10 cm of Peripheral oxygen saturation (%) 3. water) and the NIPPV group (inspiratory and expiratory pressures of 14 cm of water and 7 cm of water, respectively) were similar to those in previous studies. 15, 16 Was the trial intervention ineffective? Irrespective of the method of treatment, noninvasive ventilation produced a greater reduction in respiratory distress and metabolic abnormalities. These findings are consistent with the majority of previous studies investigating the benefits of CPAP and NIPPV [11] [12] [13] [14] 22, 23 and confirm that the therapeutic intervention in our trial was delivered successfully and appropriately. We acknowledge that the improvement in dyspnea (0.7 on a 10-point scale) was moderate, 24 but the visual-analogue scale used is a crude measure of dyspnea, and noninvasive ventilation, when not associated with patient discomfort, was associated with fewer treatment failures due to respiratory distress than was the standard treatment. Finally, despite the theoretical additional benefits of NIPPV as compared with CPAP, 10 we observed no differences in therapeutic efficacy between the two noninvasive-treatment methods. Were the meta-analyses wrong? Recent metaanalyses and systemic reviews have included numerous randomized clinical trials. However, the individual trials had small treatment groups that ranged from 9 to 65 patients, with recruitment rates of only 10 to 30% (as compared with the 62% of patients assigned to treatment in the 3CPO trial). In the meta-analyses, the total number of outcome events was below the recommended threshold of 200, 25 which limits the generalizability of their findings. There is concern about reporting, publication, and recruitment bias in individual published studies that will be compounded by pooled analyses. The discrepancy between the results of our large, randomized, controlled trial and previous pooled data is not unique, and the limitations of meta-analyses have been well documented. 26 The mortality rate in our trial was higher than the rates reported in registry data for patients with acute heart failure (6.7% in the EuroHeart Failure Survey II 27 and 4% in the Acute Decompensated Heart Failure National Registry [ADHERE] 28 ), and our participants were older than the patients in those registries and were predominantly female. These discrepancies in mortality and in patient characteristics are likely to be related to differences in the study populations. Acute heart failure registries include all patients with decompensated heart failure rather than only those with severe pulmonary edema. Indeed, in the EuroHeart Failure registry, only 16% of the patients had a qualifying diagnosis of acute pulmonary edema.
Mehta and colleagues prematurely terminated their trial comparing CPAP with NIPPV because of concerns about an increased rate of myocardial infarction in the NIPPV group. 29 A subsequent study by Bellone et al. did not replicate this finding and showed no effect of NIPPV on the rate of myocardial infarction. 30 The systematic review by Peter et al. reported a weak relationship between NIPPV and an increase in the rate of myocardial infarction. 16 This finding was largely the result of the weight given to the study by Mehta et al. in the pooled data. 26 The 3CPO trial showed no relationship between the rate of myocardial infarction and treatment with either CPAP or NIPPV.
Previous trials have indicated that the physiological improvement seen with noninvasive ventilation results in a reduction in the rate of tracheal intubation. 11, 12 Pooled data from the meta-analysis by Peter et al. suggest that six patients need to be treated with CPAP and seven with NIPPV to avert intubation and mechanical ventilation in one patient. 16 In contrast, the 3CPO trial found no benefit of noninvasive ventilation in reducing the rate of intubation, a result that may reflect the relatively low intubation rates we observed. The reasons for these low rates in our study are unclear but may be related to differences between our study and others in patient populations, concomitant therapies, and thresholds for intubation and mechanical ventilation. Given that the present and previous trials were by necessity open, there is concern about treatment bias as a result of various thresholds for intervention according to treatment allocation. For example, patients receiving standard oxygen therapy may be more likely to undergo intubation than those already gaining the apparent benefit of noninvasive ventilation.
In conclusion, noninvasive ventilatory support delivered by either CPAP or NIPPV safely provides earlier improvement and resolution of dyspnea, respiratory distress, and metabolic abnormalities than does standard oxygen therapy. However, these effects do not result in improved rates of survival. We recommend that noninvasive ventilation (CPAP or NIPPV) be considered as adjunctive therapy in patients with acute cardiogenic pulmonary edema who have severe respiratory distress or whose condition does not improve with pharmacologic therapy. No potential conflict of interest relevant to this article was reported.
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